Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208462852> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W3208462852 endingPage "566" @default.
- W3208462852 startingPage "565" @default.
- W3208462852 abstract "To date, very few treatments have been demonstrated to reduce the burden of morbidity and mortality from COVID-19. Although corticosteroids have been proven to reduce mortality in severe disease, there has been little convincing evidence on interventions that may prevent disease, reduce hospitalizations, and reduce the numbers of people progressing to critical disease and death. Ivermectin is a well-known medicine that is approved as an antiparasitic by the World Health Organization and the US Food and Drug Administration. It is widely used in lowand middle-income countries to treat worm infections. Also used for the treatment of scabies and lice, it is one of the World Health Organization’s Essential Medicines.1 With total doses of ivermectin distributed apparently equalling one-third of the present world population,1 ivermectin at the usual doses (0.2–0.4 mg/kg) is considered extremely safe for use in humans.1 In addition to its antiparasiticactivity, it has been noted to have antiviral and anti-inflammatory properties, leading to an increasing list of therapeutic indications. South African authorities approved the use of a drug used to control parasites in humans and livestock to treat coronavirus patients. Additionally, in January 2021, the South African Health Products Regulatory Authority (SAHPRA) announced that ivermectin, would be allowedfor use on compassionate grounds in a controlled-access program. Ivermectin locally has been used for the prevention and/or management of Covid-19 infection. This has resulted in a huge black market trade of ivermectin in South Africa as many health professionals and others have taken to social media and other platforms to profile this drug as an effective treatment for the covid-19 viral infection. Roman and colleagues (2021)1 conducted a systematic review and meta-analysis to evaluate treatment effects of Ivermectin (IVM) on clinical outcomes and adverse events (AEs) in people with COVID-19." @default.
- W3208462852 created "2021-11-08" @default.
- W3208462852 creator A5077227375 @default.
- W3208462852 date "2021-10-29" @default.
- W3208462852 modified "2023-09-25" @default.
- W3208462852 title "What’s new for the clinician – summaries of recently published papers" @default.
- W3208462852 cites W3174188666 @default.
- W3208462852 doi "https://doi.org/10.17159/2519-0105/2021/v76no9a8" @default.
- W3208462852 hasPublicationYear "2021" @default.
- W3208462852 type Work @default.
- W3208462852 sameAs 3208462852 @default.
- W3208462852 citedByCount "0" @default.
- W3208462852 crossrefType "journal-article" @default.
- W3208462852 hasAuthorship W3208462852A5077227375 @default.
- W3208462852 hasBestOaLocation W32084628521 @default.
- W3208462852 hasConcept C118552586 @default.
- W3208462852 hasConcept C126322002 @default.
- W3208462852 hasConcept C142724271 @default.
- W3208462852 hasConcept C16005928 @default.
- W3208462852 hasConcept C177713679 @default.
- W3208462852 hasConcept C204787440 @default.
- W3208462852 hasConcept C27415008 @default.
- W3208462852 hasConcept C2777499811 @default.
- W3208462852 hasConcept C2779134260 @default.
- W3208462852 hasConcept C2781443149 @default.
- W3208462852 hasConcept C2908647359 @default.
- W3208462852 hasConcept C2911037157 @default.
- W3208462852 hasConcept C42972112 @default.
- W3208462852 hasConcept C71924100 @default.
- W3208462852 hasConcept C99454951 @default.
- W3208462852 hasConceptScore W3208462852C118552586 @default.
- W3208462852 hasConceptScore W3208462852C126322002 @default.
- W3208462852 hasConceptScore W3208462852C142724271 @default.
- W3208462852 hasConceptScore W3208462852C16005928 @default.
- W3208462852 hasConceptScore W3208462852C177713679 @default.
- W3208462852 hasConceptScore W3208462852C204787440 @default.
- W3208462852 hasConceptScore W3208462852C27415008 @default.
- W3208462852 hasConceptScore W3208462852C2777499811 @default.
- W3208462852 hasConceptScore W3208462852C2779134260 @default.
- W3208462852 hasConceptScore W3208462852C2781443149 @default.
- W3208462852 hasConceptScore W3208462852C2908647359 @default.
- W3208462852 hasConceptScore W3208462852C2911037157 @default.
- W3208462852 hasConceptScore W3208462852C42972112 @default.
- W3208462852 hasConceptScore W3208462852C71924100 @default.
- W3208462852 hasConceptScore W3208462852C99454951 @default.
- W3208462852 hasIssue "09" @default.
- W3208462852 hasLocation W32084628521 @default.
- W3208462852 hasOpenAccess W3208462852 @default.
- W3208462852 hasPrimaryLocation W32084628521 @default.
- W3208462852 hasRelatedWork W10861589 @default.
- W3208462852 hasRelatedWork W14463965 @default.
- W3208462852 hasRelatedWork W15101666 @default.
- W3208462852 hasRelatedWork W364445 @default.
- W3208462852 hasRelatedWork W5780226 @default.
- W3208462852 hasRelatedWork W6335962 @default.
- W3208462852 hasRelatedWork W6828997 @default.
- W3208462852 hasRelatedWork W9693862 @default.
- W3208462852 hasRelatedWork W9899646 @default.
- W3208462852 hasRelatedWork W17913680 @default.
- W3208462852 hasVolume "76" @default.
- W3208462852 isParatext "false" @default.
- W3208462852 isRetracted "false" @default.
- W3208462852 magId "3208462852" @default.
- W3208462852 workType "article" @default.